Cost-effective COVID Vaccine Using Newcastle Disease

Experts around the world have predicted that the pandemic may see a repeated wave which is why scientists worldwide have been trying to find a vaccine or an antiviral that can protect the people against the virus and reduce the number of deaths and cases next time. A new study reports the use of the Newcastle disease virus as a vaccine vector and its efficiency and productivity in inducing antibodies at high levels following intramuscular administration. The study presents a cost-effective way for vaccine production against SARS CoV-2. There can be a few advantages to this. They can be used as a live or an inactive vaccine and the regimen can be changed to induce predominantly Th1 or Th2 type immune reaction. They can be developed and handled in the Biosecurity Lab level 2. They also can be cultured in high numbers with the help of cell cultures or other hosts. Using this means higher yields and low manufacturing costs and that means lower cost per dose per person.

The study provides proof by conducting tests on embryonated chicken eggs. It showed the insertion of a large transgene still allowed the virus to grow inside the chicken eggs. They also observed that S-F was incorporated into the viral particles much better than the WTS, but the CoV-2 protein was successfully expressed by infected cells. It showed only the presence of S1, but the S-F was preserved in the prefusion conformation. The study concluded that with these cost-effective ways of a promising CoV-2 vaccine candidate could be generated to high yield under BSL- 2 conditions.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit

Want to set up an online consultation for your practice, Click here

Ref Link: